

S3 Table The clinical data according to each vaccination dose in the vaccinated groups

	Ca, mRNA ^{a)}	Ca, AdV ^{b)}	HCW, mRNA ^{c)}	HCW, AdV ^{d)}
First dose vaccination				
Duration from 1st vaccination to Sampling (day), median (IQR)	20 (15-23.5)	21 (13.5-27.8)	19.5 (19-20.8)	21 (20-21)
Seroconversion	38/70	15/38	6/6	11/14
S-specific antibody titer, GMT (95% CI)	1.9 (1.19-3.19)	1.2 (0.71-1.99)	23.1 (5.36-99.3)	5.6 (1.84-17.2)
Second dose vaccination				
Duration from 2nd vaccination to sampling, days, median (IQR)	20 (13-28)	16 (14-27.5)	13.5 (12.3-14)	14 (14-17.5)
Seroconversion	65/65	34/34	6/6	14/14
Spike-specific antibody titer, GMT (95% CI)	566.6 (313.4-1,024)	176.6 (102.4-304.7)	1,494 (641-3,485)	468.3 (264.6-828.7)
Third dose vaccination				
Duration from 3rd vaccination to sampling, days, median (IQR)	29 (20.5-37.5)	28 (22.5-35)	27.5 (26.3-28.8)	27.5 (22.5-34)
Seroconversion	11/11	26/26	6/6	14/14
S-specific antibody titer, GMT (95% CI)	8,810 (4,874-15,926)	3,744 (2,138-6,559)	9,866 (7,005-13,896)	7,835 (6,102-10,059)

CI, confidence interval; GMT, geometric mean titer; IQR, interquartile range; S, spike. ^{a)}Cancer patients who received a primary series of mRNA vaccine (either BNT162b2 or mRNA-1273), ^{b)}Cancer patients who received a primary series of adenovirus vector vaccine (AZD1222), ^{c)}Healthcare workers who received a primary series of mRNA vaccine (either BNT162b2 or mRNA-1273), ^{d)}Healthcare workers who received a primary series of adenovirus vector vaccine (AZD1222).